Kyle Rasbach

Kyle Rasbach is a prominent figure in the life sciences investment sector with extensive experience in healthcare equity investment and pharmaceutical research. Here's a comprehensive overview of his career:

Education and Early Career

Kyle Rasbach holds impressive academic credentials:

• PhD and PharmD from the Medical University of South Carolina
• MBA from The Citadel
• BS from Denison University

His educational background combines pharmaceutical expertise with business acumen, setting a strong foundation for his career in healthcare investments.

Career Progression

T. Rowe Price: Rasbach served as a Vice President at T. Rowe Price, where he:

• Managed pharmaceutical, specialty pharmaceutical, and biotechnology investments
• Led T. Rowe Price's IPO investment in CoLucid Pharmaceuticals, which was later sold to Eli Lilly for nearly $1 billion1

Cowen and Company: Prior to T. Rowe Price, he worked as a Vice President, covering global pharmaceutical equities.1

Pappas Capital: In January 2018, Rasbach joined Pappas Capital as a Partner. His role at Pappas Capital evolved significantly:

• In July 2019, he was promoted to Managing Partner of Pappas Ventures, the firm's venture capital business
• In this role, he oversees Pappas Ventures and leads fundraising and investment efforts for future venture funds12

Key Achievements at Pappas Capital:

• Played an instrumental role in identifying and executing several investments, including Mirum Pharmaceuticals, CuraSen Therapeutics, and Ribometrix
• Contributed to the firm's success in raising over $540 million and guiding the launch or development of more than 85 companies since its founding in 19941

Recent Career Move

As of January 2024, Kyle Rasbach has taken on a new role:

Zentalis Pharmaceuticals:

• Appointed as Chief Business Officer
• Brings his extensive experience in biotechnology portfolio management and scientific research to drive the company's growth and value creation34

Professional Expertise

Rasbach's career showcases his expertise in:

• Healthcare equity investments
• Pharmaceutical and biotechnology sector analysis
• Venture capital management in life sciences
• Clinical pharmacology and basic science research

His diverse background, combining scientific knowledge with investment acumen, has positioned him as a respected leader in the life sciences investment community.